Načítá se...
Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials
INTRODUCTION: Interleukin (IL)-23 inhibitors are a new class of biologics currently undergoing clinical trials for the treatment of moderate-to-severe psoriasis. Phase III studies of guselkumab, an IL-23 receptor monoclonal antibody, are currently underway. METHODS: We summarize the available phase...
Uloženo v:
| Vydáno v: | Dermatol Ther (Heidelb) |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Healthcare
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5574739/ https://ncbi.nlm.nih.gov/pubmed/28639011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-017-0187-0 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|